Journals Alimentary Pharmacology & Ther...

Alimentary Pharmacology & Therapeutics
Kyle Staller, Ola Olén, Jonas Söderling, Bjorn Roelstraete, Hans Törnblom, Braden Kuo, Long H Nguyen, Jonas F Ludvigsson
BACKGROUND: The microbiome plays an important role in the pathophysiology of irritable bowel syndrome (IBS). Antibiotic use can fundamentally alter gut microbial ecology. We examined the association of antibiotic use with IBS in a large population-based investigation. METHODS: A case-control study with prospectively collected data on 29,111 adult patients diagnosed with IBS in Sweden between 2007 and 2016 matched with 135,172 controls. Using a comprehensive histopathology cohort, the Swedish Patient Register, and the Prescribed Drug Register, we identified all consecutive cases of IBS in addition to cumulative antibiotic dispensations accrued until 1 year prior to IBS (exclusionary period) for cases and time of matching for up to five general population controls matched on the basis of age, sex, country and calendar year...
September 28, 2023: Alimentary Pharmacology & Therapeutics
Nojoud Faqerah, Daniel Walker, Konstantinos Gerasimidis
BACKGROUND: Although no causative microbe has been yet identified or successfully targeted in the treatment of inflammatory bowel disease (IBD), the role of Escherichia coli in the pathogenesis of Crohn's disease has attracted considerable interest. AIM: In this review, we present a literature overview of the interactions between diet and E. coli and other Proteobacteria in the aetiology, outcomes and management of IBD and suggest future research directions. METHODS: An extensive literature search was performed to identify in vitro studies and research in animal models that explored mechanisms by which dietary components can interact with E...
September 28, 2023: Alimentary Pharmacology & Therapeutics
Maartje M van de Meeberg, Herma H Fidder, Bas Oldenburg, Janani Sundaresan, Eduard A Struys, Nahid S M Montazeri, Wout G N Mares, Nofel Mahmmod, Dirk P van Asseldonk, Maurice W M D Lutgens, Johan P Kuyvenhoven, Svend T Rietdijk, Loes H C Nissen, Parweez Koehestanie, Nanne K H de Boer, Robert de Jonge, Gerd Bouma, Maja Bulatović Ćalasan
BACKGROUND: Therapeutic drug monitoring (TDM) has the potential to improve efficacy and diminish side effects. Measuring methotrexate-polyglutamate (MTX-PG) in erythrocytes might enable TDM for methotrexate in patients with Crohn's disease (CD). AIM: To investigate the relationship between MTX-PGs and methotrexate drug survival, efficacy and toxicity METHODS: In a multicentre prospective cohort study, patients with CD starting subcutaneous methotrexate without biologics were included and followed for 12 months...
September 28, 2023: Alimentary Pharmacology & Therapeutics
Ronnie Fass, Michael Vaezi, Prateek Sharma, Rena Yadlapati, Barbara Hunt, Tom Harris, Neila Smith, Eckhard Leifke, David Armstrong
BACKGROUND: Non-erosive reflux disease (NERD) symptoms are often episodic, making on-demand treatment an attractive treatment approach. AIMS: We compared the efficacy and safety of on-demand vonoprazan versus placebo in patients with NERD. METHODS: Patients with NERD, defined as heartburn for ≥6 months and for ≥4/7 consecutive days with normal endoscopy, received once-daily vonoprazan 20 mg during a 4-week run-in period...
September 26, 2023: Alimentary Pharmacology & Therapeutics
Yun Kim, Shi-Ra Lee, Sang Won Lee
BACKGROUND: 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which is an enzyme that converts cortisone to cortisol, plays a role in the regulation of glucose metabolism and inflammation. J2H-1702 is a novel 11β-HSD1 inhibitor, and the inhibition of 11β-HSD1 has been shown to improve insulin sensitivity, reduce inflammation, and prevent the development of nonalcoholic steatohepatitis (NASH) in preclinical models. AIMS: We aimed to assess the pharmacokinetics (PKs), pharmacodynamics (PDs), safety, and tolerability of J2H-1702 after a single-dose oral administration...
September 25, 2023: Alimentary Pharmacology & Therapeutics
Stefania Gioia, Roberto Carnevale, Daniele Tavano, Diletta Overi, Lorenzo Ridola, Silvia Nardelli, Manuela Merli, Giulia d'Amati, Adriano Pellicelli, Vincenzo Cardinale, Valerio Giannelli, Andrea Baiocchini, Oliviero Riggio, Eugenio Gaudio, Guido Carpino
BACKGROUND: Porto-sinusoidal vascular disorder (PSVD) is characterised by lesions involving portal veins and sinusoids in absence of cirrhosis with an unclear pathophysiology. However, its association with immunodeficiency, bowel disorders and abdominal bacterial infections supports the role of altered intestinal permeability and gut-derived endotoxins. The study aimed at assessing the association between serological markers of increased intestinal permeability, pro-aggregating/procoagulant state and liver injury in PSVD and portal hypertension...
September 20, 2023: Alimentary Pharmacology & Therapeutics
David Bergman, Bjorn Roelstraete, Jiangwei Sun, Fahim Ebrahimi, Johan Askling, Jonas F Ludvigsson
BACKGROUND: Microscopic colitis (MC) has been linked to several autoimmune conditions. Results from previous studies on the association with rheumatoid arthritis (RA) have been inconsistent. AIM: To assess the risk of future RA in MC. METHODS: We conducted a nationwide matched cohort study in Sweden of 8179 patients with biopsy-verified MC (diagnosed in 2007-2017), 36,400 matched reference individuals and 8202 siblings without MC, with follow-up until 2021...
September 20, 2023: Alimentary Pharmacology & Therapeutics
L M Janssen, A Rezazadeh Ardabili, M J L Romberg-Camps, B Winkens, R J van den Broek, J Hulst, H J A Verwijs, D Keszthelyi, D M A E Jonkers, A A van Bodegraven, M J Pierik, Z Mujagic
BACKGROUND: Abdominal pain is highly prevalent in patients with inflammatory bowel disease (IBD) in remission, but the aetiology is incompletely understood. AIM: To investigate the association of clinical, lifestyle and psychosocial factors with abdominal pain in patients with IBD in remission. METHODS: We performed a prospective multicentre study enrolling consecutive patients with IBD. Data were collected between 1 January 2020 and 1 July 2021, using myIBDcoach, an established remote monitoring platform for IBD...
September 19, 2023: Alimentary Pharmacology & Therapeutics
Johnny T K Cheung, Xinrong Zhang, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip, Huapeng Lin, Guanlin Li, Howard Ho-Wai Leung, Jimmy Che-To Lai, Sanjiv Mahadeva, Nik Raihan Nik Mustapha, Xiao-Dong Wang, Wen-Yue Liu, Vincent Wai-Sun Wong, Wah-Kheong Chan, Ming-Hua Zheng
BACKGROUND: Early screening may prevent fibrosis progression in metabolic-associated fatty liver disease (MAFLD). AIMS: We developed and validated MAFLD fibrosis score (MFS) for identifying advanced fibrosis (≥F3) among MAFLD patients. METHODS: This cross-sectional, multicentre study consecutively recruited MAFLD patients receiving tertiary care (Malaysia as training cohort [n = 276] and Hong Kong and Wenzhou as validation cohort [n = 431])...
September 19, 2023: Alimentary Pharmacology & Therapeutics
Stefan Schreiber, Gerhard Rogler, Mamoru Watanabe, Séverine Vermeire, Christian Maaser, Silvio Danese, Margaux Faes, Paul Van Hoek, Jeremy Hsieh, Ulrik Moerch, Yan Zhou, Angela de Haas, Christine Rudolph, Alessandra Oortwijn, Edward V Loftus
BACKGROUND: Filgotinib 200 mg (FIL200) is an approved treatment for adults with moderately to severely active ulcerative colitis (UC). AIM: To report integrated safety data from the phase 2b/3 SELECTION study (NCT02914522) and its ongoing long-term extension study SELECTIONLTE (NCT02914535). METHODS: Safety outcomes were analysed in adults with moderately to severely active UC who received FIL200, filgotinib 100 mg (FIL100) or placebo once daily throughout the 11-week SELECTION induction study, the 47-week SELECTION maintenance study (if applicable) and SELECTIONLTE (if applicable)...
September 18, 2023: Alimentary Pharmacology & Therapeutics
Naim Alkhouri, Donald Lazas, Rohit Loomba, Juan P Frias, Shibao Feng, Leo Tseng, Kemal Balic, Germaine D Agollah, Tinna Kwan, Janani S Iyer, Linda Morrow, Hank Mansbach, Maya Margalit, Stephen A Harrison
BACKGROUND: An approved therapy for nonalcoholic steatohepatitis (NASH) and fibrosis remains a major unmet medical need. AIM: To investigate the histological and metabolic benefits of pegozafermin, a glycoPEGylated FGF21 analogue, in subjects with biopsy-confirmed NASH. METHODS: This proof-of-concept, open-label, single-cohort study, part 2 of a phase 1b/2a clinical trial, was conducted at 16 centres in the United States. Adults (age 21-75 years) with NASH (stage 2 or 3 fibrosis, NAS≥4) and magnetic resonance imaging proton density fat fraction (MRI-PDFF) ≥8% received subcutaneous pegozafermin 27 mg once weekly for 20 weeks...
September 18, 2023: Alimentary Pharmacology & Therapeutics
Tiffany Wu, May Hagiwara, Esteban Gnass, Hannah Barman, David Sasson, William Treem, Kaili Ren, Ed G Marins, Chitra Karki, Harmeet Malhi
BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is caused by mutations in SERPINA1, which encodes alpha-1 antitrypsin, a protease inhibitor (Pi). Individuals with AATD and the homozygous Pi*ZZ genotype have variable risk of progressive liver disease but the influence of comorbid lung disease is poorly understood. AIMS: To characterise patients with AATD Pi*ZZ and liver disease (AATD-LD-Pi*ZZ) with or without lung disease and describe liver disease-related clinical events longitudinally...
September 17, 2023: Alimentary Pharmacology & Therapeutics
Ashwani K Singal, Yong-Fang Kuo
BACKGROUND: Data comparing waitlist and post-transplant outcomes of liver transplantation (LT) alone (LTA) versus simultaneous liver kidney (SLK) listings are limited. AIM: To examine 90-days waitlist and 1-year post-transplant outcomes of LT listings since Organ Procurement Transplant Network (OPTN) policy for SLK, who had cirrhosis with eGFR <30 mL/min or on dialysis at listing. METHODS: Adults (08/2017-03/2021) with first LT listing (2628 SLK) were stratified on renal function from listing: acute kidney injury (AKI): rise of serum creatinine by ≥0...
September 13, 2023: Alimentary Pharmacology & Therapeutics
Nabil Noureddin, Veeral Ajmera, Jaclyn Bergstrom, Richele Bettencourt, Daniel Q Huang, Harris Siddiqi, Abdul M Majzoub, Tarek Nayfeh, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramzan Idilman, Mesut Gumussoy, Digdem Kuru Oz, Ayse Erden, Rohit Loomba
BACKGROUND: There are limited data regarding the longitudinal association between MEFIB-Index (MRE combined with FIB-4) versus MAST-Score (MRI-aspartate aminotransferase) and hepatic decompensation. AIM: To examine the longitudinal association between MEFIB-Index versus MAST-Score in predicting hepatic decompensation in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: This was a longitudinal, retrospective analysis of subjects from United States, Japan, and Turkey who underwent a baseline MRE and MRI-PDFF and were followed for hepatic decompensation...
September 11, 2023: Alimentary Pharmacology & Therapeutics
Pojsakorn Danpanichkul, Cheng Han Ng, Mark D Muthiah, Kwanjit Duangsonk, Jie Ning Yong, Darren Jun Hao Tan, Wen Hui Lim, Zhen Yu Wong, Nicholas Syn, Tsubasa Tsusumi, Hirokazu Takahashi, Mohammad Shadab Siddiqui, Vincent Wai-Sun Wong, Christos S Mantzoros, Daniel Q Huang, Mazen Noureddin, Rohit Loomba, Arun J Sanyal, Karn Wijarnpreecha
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) represents a significant health threat worldwide. The growing trend towards an aging population, along with an alarming rise in obesity and diabetes, may have significant implications for the burden of NAFLD. AIM: To assess the impact of NAFLD on the elderly. METHODS: We utilised data from the Global Burden of Disease study between 2010 and 2019 to conduct a comprehensive analysis of the prevalence, mortality, and disability-adjusted life years (DALYs) associated with NAFLD in the elderly (65-89 years), stratified by region, nation, sociodemographic Index and sex...
September 11, 2023: Alimentary Pharmacology & Therapeutics
Eunju Kim, Hyun Woong Lee, Soon Sun Kim, Eileen Yoon, Eun Sun Jang, Jong-In Chang, Young Youn Cho, Gi Hyeon Seo, Hyung Joon Kim
BACKGROUND: As tenofovir disoproxil fumarate (TDF) requires long-term use, a reduction in bone density should be considered a possibility when treating patients with chronic hepatitis B (CHB) with aging and systemic diseases. Patients treated with tenofovir alafenamide (TAF) have improved bone mineral density loss compared to patients treated with TDF. Although improvements in bone density caused by TAF have been reported, studies on the actual reduction of fractures are insufficient...
September 11, 2023: Alimentary Pharmacology & Therapeutics
Kamal Kajal, Madhumita Premkumar, Manhal Izzy, Anand V Kulkarni, Ajay Kumar Duseja, Smita Divyaveer, Sekar Loganathan, Bhupendra Sihag, Ankur Gupta, Ajay Bahl, Sahaj Rathi, Sunil Taneja, Arka De, Nipun Verma, Navneet Sharma, Harpreet Kaur, Deepy Zohmangaihi, Vishesh Kumar, Harish Bhujade, Sreedhara B Chaluvashetty, Naveen Kalra
BACKGROUND: Point-of-care echocardiography (POC-Echo) is an essential intensive care hemodynamic monitoring tool. AIMS: To assess POC-Echo parameters [i.e., cardiac index (CI), systemic vascular resistance index (SVRI) and cirrhotic cardiomyopathy (CCM) markers] and serum biomarkers in predicting circulatory failure (need for vasopressors) and mortality in patients with acute-on-chronic liver failure (ACLF) having sepsis-induced hypotension. METHODS: We performed serial POC-Echo within 6 hours (h) of presentation and subsequently at 24, 48 and 72 h in patients with ACLF and sepsis-induced hypotension admitted to our liver intensive care unit...
September 9, 2023: Alimentary Pharmacology & Therapeutics
Yuk Kam Yau, Qi Su, Zhilu Xu, Whitney Tang, Jessica Y L Ching, Joyce Wing Yan Mak, Chun Pan Cheung, Matthew Fung, Margaret Ip, Paul Kay Sheung Chan, Justin Che Yuen Wu, Francis Ka Leung Chan, Siew C Ng
BACKGROUND: Faecal microbiota transplantation (FMT) has been shown to improve symptoms in a proportion of patients with irritable bowel syndrome (IBS). AIM: We performed a randomised trial to assess the efficacy of FMT in patients with IBS. METHODS: We randomised 56 patients with diarrhoea-predominant IBS 1:1 to FMT or placebo via the duodenal route at baseline and week 4. The primary outcome was > 50 points decrease in IBS severity scoring system (IBS-SSS) score at week 12...
September 5, 2023: Alimentary Pharmacology & Therapeutics
(no author information available yet)
No abstract text is available yet for this article.
September 3, 2023: Alimentary Pharmacology & Therapeutics
Huapeng Lin, Jimmy Che-To Lai, Grace Lai-Hung Wong, Adèle Delamarre, Sang Hoon Ahn, Guanlin Li, Beom Kyung Kim, Lilian Yan Liang, Hye Won Lee, Sherlot Juan Song, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim, Terry Cheuk-Fung Yip
BACKGROUND: Baveno VII was proposed for non-invasive identification of clinically significant portal hypertension. However, a substantial proportion of patients is classified in the grey zone (i.e., liver stiffness 15-24.9 kPa and/or platelet count <150 × 109 /L). AIMS: To evaluate the risk and predictors of hepatic decompensation in patients in the grey zone, and to determine the prognostic role of spleen stiffness measurement. METHODS: We included prospective cohorts (from Hong Kong, Korea and France) of patients who had undergone transient elastography examination for chronic liver disease...
August 30, 2023: Alimentary Pharmacology & Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.